Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?

Barbara Jereczek-Fossa, Jacek Jassem, Hanna Karnicka-Młodkowska, Andrzej Badzio, Renata Moś-Antkowiak, Kazimierz Krawczyk, Edmund Kowal, Anna Pilarska-Machowicz, Elzbieta Radzikowska, Kazimiera Malak

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The correlation between chemotherapy-induced toxicity and treatment outcome in cancer patients has not been studied thoroughly. Our aim was to evaluate whether there is any relationship between chemotherapy-induced leukopenia and response to treatment in small-cell lung cancer (SCLC). Data derived from records of 228 patients treated within two prospective multicentre phase II studies were analysed. In the first study (101 patients) chemotherapy included vincristine, epirubicin and cyclophosphamide and, in the second (127 patients), cyclophosphamide, etoposide and epirubicin; both regimens were given every 3 weeks. In the present analysis, the correlation between treatment outcome (response rate and survival) and highest scores of leukopenia within the first two and up to the fourth chemotherapy cycle, respectively, was evaluated. The objective response rate for the entire group was 66%; 53% in patients whose white blood cells remained normal and 85% in those who developed leukopenia within the first two cycles (P = 0.000). In multifactorial analysis, also including other treatment- and patient-related factors, independent correlation with response to chemotherapy was found for leukopenia (P = 0.001), chemotherapy regimen (P = 0.002) and the combined relative dose intensity (P = 0.018), but not for patient sex, age, performance status, pre-study weight loss, extent of disease and initial white blood cell count. Leukopenia within the first two cycles of chemotherapy was not correlated with survival, whereas such correlation for leukopenia occurring up to the fourth cycle was at the borderline level (P = 0.06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC.

Original languageEnglish
Pages (from-to)106-112
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume124
Issue number2
DOIs
Publication statusPublished - 1998

Fingerprint

Small Cell Lung Carcinoma
Leukopenia
Drug Therapy
Epirubicin
Cyclophosphamide
Vincristine
Etoposide
Leukocyte Count
Weight Loss
Neoplasms
Leukocytes
Survival Rate
Survival
Therapeutics

Keywords

  • Dose intensity
  • Leukopenia
  • Small-cell lung cancer
  • Tumour response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jereczek-Fossa, B., Jassem, J., Karnicka-Młodkowska, H., Badzio, A., Moś-Antkowiak, R., Krawczyk, K., ... Malak, K. (1998). Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer? Journal of Cancer Research and Clinical Oncology, 124(2), 106-112. https://doi.org/10.1007/s004320050141

Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer? / Jereczek-Fossa, Barbara; Jassem, Jacek; Karnicka-Młodkowska, Hanna; Badzio, Andrzej; Moś-Antkowiak, Renata; Krawczyk, Kazimierz; Kowal, Edmund; Pilarska-Machowicz, Anna; Radzikowska, Elzbieta; Malak, Kazimiera.

In: Journal of Cancer Research and Clinical Oncology, Vol. 124, No. 2, 1998, p. 106-112.

Research output: Contribution to journalArticle

Jereczek-Fossa, B, Jassem, J, Karnicka-Młodkowska, H, Badzio, A, Moś-Antkowiak, R, Krawczyk, K, Kowal, E, Pilarska-Machowicz, A, Radzikowska, E & Malak, K 1998, 'Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?', Journal of Cancer Research and Clinical Oncology, vol. 124, no. 2, pp. 106-112. https://doi.org/10.1007/s004320050141
Jereczek-Fossa, Barbara ; Jassem, Jacek ; Karnicka-Młodkowska, Hanna ; Badzio, Andrzej ; Moś-Antkowiak, Renata ; Krawczyk, Kazimierz ; Kowal, Edmund ; Pilarska-Machowicz, Anna ; Radzikowska, Elzbieta ; Malak, Kazimiera. / Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?. In: Journal of Cancer Research and Clinical Oncology. 1998 ; Vol. 124, No. 2. pp. 106-112.
@article{0d35fd7807e44606825a857780c796d8,
title = "Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?",
abstract = "The correlation between chemotherapy-induced toxicity and treatment outcome in cancer patients has not been studied thoroughly. Our aim was to evaluate whether there is any relationship between chemotherapy-induced leukopenia and response to treatment in small-cell lung cancer (SCLC). Data derived from records of 228 patients treated within two prospective multicentre phase II studies were analysed. In the first study (101 patients) chemotherapy included vincristine, epirubicin and cyclophosphamide and, in the second (127 patients), cyclophosphamide, etoposide and epirubicin; both regimens were given every 3 weeks. In the present analysis, the correlation between treatment outcome (response rate and survival) and highest scores of leukopenia within the first two and up to the fourth chemotherapy cycle, respectively, was evaluated. The objective response rate for the entire group was 66{\%}; 53{\%} in patients whose white blood cells remained normal and 85{\%} in those who developed leukopenia within the first two cycles (P = 0.000). In multifactorial analysis, also including other treatment- and patient-related factors, independent correlation with response to chemotherapy was found for leukopenia (P = 0.001), chemotherapy regimen (P = 0.002) and the combined relative dose intensity (P = 0.018), but not for patient sex, age, performance status, pre-study weight loss, extent of disease and initial white blood cell count. Leukopenia within the first two cycles of chemotherapy was not correlated with survival, whereas such correlation for leukopenia occurring up to the fourth cycle was at the borderline level (P = 0.06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC.",
keywords = "Dose intensity, Leukopenia, Small-cell lung cancer, Tumour response",
author = "Barbara Jereczek-Fossa and Jacek Jassem and Hanna Karnicka-Młodkowska and Andrzej Badzio and Renata Moś-Antkowiak and Kazimierz Krawczyk and Edmund Kowal and Anna Pilarska-Machowicz and Elzbieta Radzikowska and Kazimiera Malak",
year = "1998",
doi = "10.1007/s004320050141",
language = "English",
volume = "124",
pages = "106--112",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?

AU - Jereczek-Fossa, Barbara

AU - Jassem, Jacek

AU - Karnicka-Młodkowska, Hanna

AU - Badzio, Andrzej

AU - Moś-Antkowiak, Renata

AU - Krawczyk, Kazimierz

AU - Kowal, Edmund

AU - Pilarska-Machowicz, Anna

AU - Radzikowska, Elzbieta

AU - Malak, Kazimiera

PY - 1998

Y1 - 1998

N2 - The correlation between chemotherapy-induced toxicity and treatment outcome in cancer patients has not been studied thoroughly. Our aim was to evaluate whether there is any relationship between chemotherapy-induced leukopenia and response to treatment in small-cell lung cancer (SCLC). Data derived from records of 228 patients treated within two prospective multicentre phase II studies were analysed. In the first study (101 patients) chemotherapy included vincristine, epirubicin and cyclophosphamide and, in the second (127 patients), cyclophosphamide, etoposide and epirubicin; both regimens were given every 3 weeks. In the present analysis, the correlation between treatment outcome (response rate and survival) and highest scores of leukopenia within the first two and up to the fourth chemotherapy cycle, respectively, was evaluated. The objective response rate for the entire group was 66%; 53% in patients whose white blood cells remained normal and 85% in those who developed leukopenia within the first two cycles (P = 0.000). In multifactorial analysis, also including other treatment- and patient-related factors, independent correlation with response to chemotherapy was found for leukopenia (P = 0.001), chemotherapy regimen (P = 0.002) and the combined relative dose intensity (P = 0.018), but not for patient sex, age, performance status, pre-study weight loss, extent of disease and initial white blood cell count. Leukopenia within the first two cycles of chemotherapy was not correlated with survival, whereas such correlation for leukopenia occurring up to the fourth cycle was at the borderline level (P = 0.06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC.

AB - The correlation between chemotherapy-induced toxicity and treatment outcome in cancer patients has not been studied thoroughly. Our aim was to evaluate whether there is any relationship between chemotherapy-induced leukopenia and response to treatment in small-cell lung cancer (SCLC). Data derived from records of 228 patients treated within two prospective multicentre phase II studies were analysed. In the first study (101 patients) chemotherapy included vincristine, epirubicin and cyclophosphamide and, in the second (127 patients), cyclophosphamide, etoposide and epirubicin; both regimens were given every 3 weeks. In the present analysis, the correlation between treatment outcome (response rate and survival) and highest scores of leukopenia within the first two and up to the fourth chemotherapy cycle, respectively, was evaluated. The objective response rate for the entire group was 66%; 53% in patients whose white blood cells remained normal and 85% in those who developed leukopenia within the first two cycles (P = 0.000). In multifactorial analysis, also including other treatment- and patient-related factors, independent correlation with response to chemotherapy was found for leukopenia (P = 0.001), chemotherapy regimen (P = 0.002) and the combined relative dose intensity (P = 0.018), but not for patient sex, age, performance status, pre-study weight loss, extent of disease and initial white blood cell count. Leukopenia within the first two cycles of chemotherapy was not correlated with survival, whereas such correlation for leukopenia occurring up to the fourth cycle was at the borderline level (P = 0.06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC.

KW - Dose intensity

KW - Leukopenia

KW - Small-cell lung cancer

KW - Tumour response

UR - http://www.scopus.com/inward/record.url?scp=15444352577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444352577&partnerID=8YFLogxK

U2 - 10.1007/s004320050141

DO - 10.1007/s004320050141

M3 - Article

VL - 124

SP - 106

EP - 112

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -